Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma AB announced a reorganization of its European and International Commercial and Medical Affairs operations to enhance performance and predictability in 2026. The changes include appointing Max Sakajja as Vice President, General Manager Europe and International, and implementing operational adjustments to improve accountability and collaboration. These strategic moves aim to support the company’s growth in Europe and the UK, improve transparency and forecasting, and position Hansa Biopharma for sustainable revenue growth.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, a first-in-class IgG antibody-cleaving enzyme therapy, and HNSA-5487, a next-generation IgG cleaving molecule. Hansa Biopharma is based in Lund, Sweden, with operations in Europe and the U.S., and is listed on Nasdaq Stockholm.
Average Trading Volume: 742,124
Technical Sentiment Signal: Hold
Current Market Cap: SEK3.65B
Find detailed analytics on HNSA stock on TipRanks’ Stock Analysis page.